You can consult here the latest guidelines for the management of CMV in Solid Organ Transplantation published in 2018 by an international multidisciplinary panel of experts, with the Transplantation Society. Highlights include advances in molecular and immunologic diagnostics, improved understanding of diagnostic thresholds, optimized methods of prevention, advances in the use of novel antiviral therapies and certain immunosuppressive agents, and more savvy approaches to treatment resistant/refractory disease.

Our medical experts have created this comprehensive overview of maribavir in clearing CMV viraemia and improving symptom control in both solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients with refractory/resistant CMV infection/disease.

Prof. A. Le Moine en Dr. T. Van Meerhaeghe, nefrologen in het Erasmus ziekenhuis in Brussel, delen hun ervaring met Livtencity 1 jaar na lancering. 

Lees met ons mee over de nieuwste ontwikkelingen, therapeutische strategieën en inzichten in CMV management na transplantatie.

Follow Prof. Dr. Dirk Kuypers presenting two detailed cases of patients with CMV infections developed after kidney transplantations. The first patient case is of a 41 year-old female patient with hereditary kidney disease who received her first transplant in 2006 and developed a refractory CMV infection after being treated previously with 2 lines of therapy. The second patient case involves a 58-year-old male patient with diabetic nephropathy who received his first kidney transplant in 2019 and developed CMV-related complications right after.

Prof. Dr. Nicholas Kneidinger, a renowned expert in lung transplantation from a lung transplantation center in Munich, shares insights from his extensive background in managing CMV. He discusses the newly introduced maribavir for treating resistant and refractory CMV infections, presenting two case studies of patients who underwent double lung transplants.

Solstice trial

Naam van het geneesmiddel : LIVTENCITY 200 mg filmomhulde tabletten
Therapeutische indicaties:
LIVTENCITY is geïndiceerd voor de behandeling van cytomegalovirus (CMV)-infectie en/of -ziekte die refractair zijn (met of zonder resistentie) voor een of meerdere eerdere therapieën, waaronder ganciclovir, valganciclovir, cidofovir of foscarnet bij volwassen patiënten die een hematopoëtische stamceltransplantatie (HSCT) of een solide-orgaantransplantatie (SOT) hebben ondergaan
Farmacotherapeutische categorie: Antivirusmiddelen voor systemisch gebruik, direct werkzame antivirusmiddelen, ATC-code: J05AX10
Werkingsmechanisme: 

Bekijk de terugbetaling van LIVTENCITY®

Mechanism of action of livtencity